Beats Medical

What Beats Medical does

Beats Medical Limited (trading as Beats Medical, incorporated as Beats Therapeutics Limited, Ireland company number 619940) is a Dublin-based digital therapeutics company founded in 2013 by chartered physiotherapist Dr Ciara Clancy. The company develops the Colbolt© platform, a patented AI/ML-powered DTx architecture that delivers objective digital assessments and tailored therapies via smartphone applications for central nervous system (CNS) and rare conditions, using built-in sensors (accelerometer, gyroscope, microphone) without additional hardware. The product portfolio spans four consumer-facing apps — the prescription-only Parkinson's app (mobility, speech, dexterity), Dystant Galaxy for pediatric Dyspraxia, Wonders Cape for child wellbeing, and the Branches clinical research app — plus B2B services including digital consulting, observational study solutions, clinical trial solutions, and data insights powered by Colbolt.

The company operates a dual-track go-to-market: (1) B2B pharma, where Colbolt is white-labeled or co-branded into the clinical pipelines of Top 10 Global Pharma companies from pre-clinical through commercialization; and (2) direct-to-consumer subscriptions (€30.40/month or €330/year) via iOS and Android app stores with a 14-day free trial, supplemented by insurance reimbursement through Vhi (Ireland's largest private health insurer, covering 1.2M+ customers for the Dyspraxia app). Revenue streams comprise consumer subscription recurring fees, pharma platform licensing and royalties, digital consulting professional services, and managed insurance reimbursement. Beats Medical is ISO 13485 certified, employs 1-10 people, and operates from Sandyford, Dublin, with commercial users across 30+ countries.

Name

Beats Medical

Legal name

Beats Therapeutics Limited

Website

https://beatsmedical.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Beats Medical develops the Colbolt© AI/ML digital therapeutics platform that delivers objective assessments and tailored therapies via smartphone apps for CNS and rare conditions, serving pharmaceutical companies (clinical trials), individual Parkinson's and Dyspraxia patients via subscription apps, and insurers through Vhi reimbursement.

Ownership category

akta.pro rank

Product category

Digital Therapeutics

NAICS

Other Scientific and Technical Consulting Services (54169), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Scientific Research and Development Services (5417)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)

akta.pro secondary industries

Decentralized/Hybrid Trial Enablement (DCT) Platforms (HLACAOAL), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Digital therapeutics
• Clinical trial technology
• Parkinson's disease apps
• Digital biomarkers
• Mobile health assessments

Headquarters

HQ city

Dublin

HQ country

Ireland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. Consumer App Subscriptions (Parkinson's): Direct-to-consumer subscription for the Beats Medical Parkinson's Therapy app. Two tiers: Monthly subscription at €30.40/month (daily charge of €1.00) paid by direct debit; Annual subscription at €330/year (€27.50/month equivalent). Subscriptions auto-renew annually. 14-day free trial available for conversion. Services include daily tailored walking metronome therapy, speech exercises, dexterity exercises, calendar medication reminders, and monthly progress reports. The app is prescription-only and intended for home use.
2. Consumer App Subscriptions (Dyspraxia / Dystant Galaxy): Direct-to-consumer subscription for the Beats Medical Dyspraxia app (Dystant Galaxy). Offers a 'Base Level' free trial program followed by paid program packages for Gross Motor Galaxy, Fine Motor Meteor, Speech Station, or a combined Program Package. Available on iOS and Android app stores.
3. Pharma Partnership — White-Label / Co-Branded Platform Licensing: Beats Medical deploys its Colbolt platform in white-labeled or co-branded solutions embedded into pharmaceutical company clinical pipelines, from pre-clinical through commercialization. Revenue derives from licensing the platform for use in clinical trials (assessment-only or full DTx), with partners including Top 10 Global Pharma companies. This is the primary B2B revenue stream targeting precision digital assessments and digital therapeutic solutions for CNS and rare conditions.
4. Digital Consulting Services: Beats Medical provides strategic digital consulting to pharmaceutical companies to define digital strategy for evidence generation, covering the Understand-Decide-Define framework. Deliverables include research, business case development, and a detailed digital product deployment roadmap including system architecture, data models, and risk management. Consulting supports adoption of the Colbolt platform for clinical trials and post-market surveillance.
5. Insurance Reimbursement (Vhi Partnership): The Beats Medical Dyspraxia app is directly reimbursed by Ireland's largest private health insurer, Vhi, providing coverage for more than 1.2 million customers. This creates a third-party payer revenue stream where insurers reimburse the digital therapeutic, expanding beyond direct consumer payments.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Beats Medical develops the Colbolt© intelligent Digital Therapeutics platform, an AI/ML-powered smartphone-based system that delivers objective digital assessments and tailored therapies for CNS and rare conditions without requiring additional hardware. The company sells B2B licensing of the Colbolt platform to pharmaceutical companies for use in clinical trials (white-label or co-branded) and offers B2C subscription consumer apps for Parkinson's patients and children with Dyspraxia, complemented by digital consulting services and observational/clinical trial solutions.

Product overview

Beats Medical offers a unified platform architecture centered on the Colbolt© intelligent DTx platform, which powers objective digital assessments and tailored digital therapies for CNS and rare conditions. The product portfolio includes the core Colbolt© Platform for pharmaceutical partners, supplemented by consumer-facing therapy applications: the Parkinson's App addressing mobility, speech and dexterity symptoms; the Dystant Galaxy app for children's dyspraxia; the Wonders Cape wellbeing app for children; and the Branches app for clinical research participants. Service offerings encompass Digital Consulting, Observational Study Solutions, Clinical Trial Solutions, and Data Insights—all leveraging the Colbolt© technology to deliver AI-powered assessments via smartphone with no additional hardware required.

Differentiator

Problem solved

Functional benefit

Brands

• Colbolt: Intelligent DTx platform with patented AI and ML technology powering objective assessments and tailored digital therapeutics through smartphone applications.
• Dystant Galaxy
• Wonders Cape
• Branches

Products and services

• Colbolt© Platform Beats Medical's intelligent Digital Therapeutics platform based on patented AI and ML processes that delivers objective digital assessments and tailored therapies across multiple CNS and rare conditions. Requires no additional hardware and deploys via smartphone applications (iOS and Android). Powers both consumer apps and white-label/co-branded pharma clinical trial deployments.
• Beats Medical Parkinson's Therapy App Award-winning prescription-only digital therapy app for individuals diagnosed with Parkinson's Disease. Addresses Mobility (tailored walking metronome therapy), Speech (language exercises with real-time feedback on volume and intensity), and Dexterity (hand exercises) symptoms. Available for home use via monthly (€30.40/month) or annual (€330/year) subscription with 14-day free trial, excluding the US.
• Dystant Galaxy (Dyspraxia App) Interactive therapy app for children aged 5-14 with Dyspraxia or Developmental Coordination Disorder. Delivers daily exercises through space-themed gamified activities targeting gross motor (Gross Motor Galaxy), fine motor (Fine Motor Meteor), speech and communication (Speech Station) skills, with a combined Program Package available. Available on iOS and Android with base level free trial and paid program packages.
• Wonders Cape App

Quantifiable outcome

• 5-fold increase in data precision vs. traditional methods
• +7 more outcomes

Named customers6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability7 records

Feature7 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• Top 10 Global Pharmaceutical CompaniescoreStrategic or Co-development PartnerBeats Medical partners with leading pharmaceutical companies to improve real-world data and evidence collection, from pre-clinical stages to drug commercialization. The company deploys its Colbolt platform as white-labeled or co-branded solutions embedded in pharma pipelines, delivering precision digital assessments to enhance R&D activities and providing tailored digital therapies that drive long-term behavioral change. Over 85% of CNS drug trials fail due to insufficient outcome measures — Beats Medical addresses this core challenge with objective digital assessments.
• VhicoreChannel Partner/ Reseller/ DistributorVhi, Ireland's largest private health insurer, partnered with Beats Medical to provide direct reimbursement coverage for the Dyspraxia app for children. The partnership covers over 1.2 million Vhi customers. This is a flagship insurance reimbursement model for digital therapeutics in Ireland. Vhi stated: 'Technology like this can significantly improve condition management for our customers' lives because it's more convenient, engaging, and in this case, it may even be a game-changer.'
• Portuguese MS Society (SPEM)coreStrategic or Co-development PartnerBeats Medical partnered with SPEM on a usability study deploying the Colbolt Platform to digitize mobility assessments for Multiple Sclerosis patients. The collaboration produced a whitepaper titled 'Reimagining Mobility Assessments in MS,' reflecting a shared commitment to driving breakthroughs informed by patient voices, experiences, and insights. SPEM's endorsement validates the platform's applicability across a broad range of CNS conditions beyond Parkinson's.
• Trinity College DublinsupportingStrategic or Co-development PartnerTrinity College Dublin conducted research on Beats Medical's digitised 2-Minute Walk Test (2MWT), demonstrating a Pearson correlation of r=0.98 versus gold-standard clinician-administered assessment. This independent academic validation provides rigorous clinical evidence for the platform's accuracy and reliability in measuring mobility.
• OurMobileHealthsupportingOthersOurMobileHealth, a panel of independent digital health experts, conducted a detailed analysis of the Beats Medical app across multiple areas. Beats Medical scored 100% in Regulatory Approval, Security, Effectiveness, Usability, and Technical Stability, achieving an overall average of 98%. This independent validation enhances credibility with healthcare providers and insurers.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Akili Interactive: Prescription digital therapeutics company (EndeavorRx) operating in the same regulated DTx category as Beats Medical's Parkinson's app. Targets neurological conditions with software-based therapies and pursues pharma partnerships, directly competing for payer and prescriber attention.
• Voluntis (Aptar Digital Health): Digital therapeutics company developing software-based therapy companions, particularly in oncology and chronic disease. Comparable to Beats Medical in prescription DTx positioning and pharma co-development models.
• Click Therapeutics: Prescription digital therapeutics company developing software-based treatments across CNS indications, including major pharma collaborations. Overlaps with Beats Medical's Colbolt platform in CNS conditions, prescription DTx positioning, and pharma commercialization partnerships.
• Koneksa Health: Digital biomarker company providing wearable and smartphone-based assessments for clinical trials in CNS and other therapeutic areas. Direct overlap with Beats Medical's Colbolt platform in pharma clinical trial digital endpoints and decentralized assessment.
• MedRhythms: Digital therapeutics company focused on neurologic conditions, leveraging sensor-based gait and walking interventions similar to Beats Medical's gross-motor metronome therapy. Competes in the same neurological DTx category with prescription-grade positioning.

Broad incumbents

• Signant Health: Large clinical trial technology provider offering eCOA, ePRO, and digital endpoint solutions to pharma across all phases. Comparable to Beats Medical's clinical trial solutions business, though Signant is a broader incumbent serving multiple therapeutic areas at greater scale.
• Biofourmis: Decentralized clinical trial and remote patient monitoring platform serving pharma across multiple therapeutic areas. Comparable to Beats Medical's Colbolt platform in DCT and clinical research deployment, though Biofourmis is broader in scope and condition coverage.

Emerging players

• CureApp: Japan-based prescription digital therapeutics company developing regulator-approved software therapies across multiple indications. Comparable to Beats Medical in regulated, prescription DTx positioning and pharma partnership model, primarily regional to Japan.
• MindMaze: Neurological digital therapeutics and digital biomarker company building AI-driven therapies for brain recovery and CNS disorders. Comparable to Beats Medical in CNS focus and pharma-adjacent go-to-market, though with a hardware-tilted platform.
• Science 37: Decentralized clinical trial operating system enabling remote participation in clinical research. Overlaps with Beats Medical's Branches app and Colbolt-powered clinical trial deployments, though Science 37 is a broader platform versus Beats Medical's condition-specific assessments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/in/ciaraclancy
• Xx.com/BeatsMedical
• Facebookfacebook.com/388649044600176

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beats Medical